Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary pulmonary hypertension: Current therapy.

Olivier Sitbon1, Marc Humbert, Gérald Simonneau

  • 1Service de Pneumologie et Réanimation Respiratoire, Pulmonary Vascular Center, Hôpital Antoine Béclère, Assistance Publique-Hôpitaux de Paris, Université Paris-Sud, Clamart, France.

Progress in Cardiovascular Diseases
|November 2, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term effects of medical treatment in patients with chronic thromboembolic pulmonary hypertension.

ERJ open research·2025
Same author

Cardiopulmonary Hemodynamic Determinants of Long-Term Survival in Sickle Cell Disease: Insights from the ETENDARD Study.

American journal of respiratory and critical care medicine·2025
Same author

Predicting Response to Switching From Phosphodiesterase Type 5 Inhibitor to Riociguat in Patients With Pulmonary Arterial Hypertension: Biomarker and Responder Analysis of the RESPITE and REPLACE Studies.

Pulmonary circulation·2025
Same author

Management of chronic thromboembolic pulmonary hypertension.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2025
Same author

Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension: Results of an International Multicenter Prospective Registry.

Journal of the American College of Cardiology·2025
Same author

Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in CTEPH: Insights From the RACE Trial.

Circulation. Cardiovascular interventions·2025
Same journal

Beyond therapeutic maximalism: Prioritization and personalization in preventive therapies.

Progress in cardiovascular diseases·2026
Same journal

Multimodality imaging of vulnerable plaque: Are we there yet? A multifaceted perspective.

Progress in cardiovascular diseases·2026
Same journal

Beyond LDL-C: Triangulating residual risk via lipoprotein(a), remnant cholesterol, and vascular inflammation.

Progress in cardiovascular diseases·2026
Same journal

COVID-19 and coronary atherosclerosis: Unmasking and accelerating?

Progress in cardiovascular diseases·2026
Same journal

Mavacamten and left ventricular dysfunction in hypertrophic cardiomyopathy with left bundle branch block.

Progress in cardiovascular diseases·2026
Same journal

Lessons from ATTR-CM clinical trials: Progress, persistent disparities, and emerging treatment dilemmas.

Progress in cardiovascular diseases·2026
See all related articles

Primary pulmonary hypertension (PPH) treatment focuses on managing symptoms and improving quality of life, as cures remain elusive. Advances in therapies like calcium-channel blockers and prostaglandins offer improved survival for PPH patients.

Area of Science:

  • Cardiovascular Medicine
  • Pulmonology
  • Pharmacology

Background:

  • Primary pulmonary hypertension (PPH) etiology is unknown, necessitating empirical treatment strategies based on pulmonary circulation pathology.
  • Despite no cure, PPH therapies have improved patient quality of life and survival over the past two decades.

Purpose of the Study:

  • To review current therapeutic approaches for primary pulmonary hypertension.
  • To discuss the efficacy of various vasodilators and emerging treatments targeting PPH pathobiology.

Main Methods:

  • Review of current PPH management, including physical activity limitation, anticoagulation, and vasodilator therapy.
  • Analysis of calcium-channel blockers' efficacy in a subset of PPH patients and prediction of response using nitric oxide inhalation.

Related Experiment Videos

  • Evaluation of prostaglandin-based therapies and intravenous epoprostenol as a "gold standard" for severe PPH.

    • Main Results:

    • Calcium-channel blockers improve symptoms and hemodynamics in 10-15% of PPH patients with acute vasodilator response.
    • Intravenous epoprostenol significantly improves exercise capacity, hemodynamics, and survival in severe PPH (NYHA class III/IV).
    • Despite improvements, epoprostenol therapy can have incomplete responses, adverse effects, and 5-year survival remains 55%.

    Conclusions:

    • Current PPH treatments focus on symptom management and improving hemodynamics, with limited success in reversing vascular remodeling.
    • Intravenous epoprostenol is the current gold standard for severe PPH, but alternative strategies are needed.
    • For refractory cases, atrioseptostomy and lung transplantation are considered as advanced treatment options.